Table I.
Baseline characteristics, RCC and PC units within 28 days from the start of AZA, and ANC on the 29th day after the start of AZA of patients in the training and the validation set.
| Characteristics | Training set (n=143) | Validation set (n=69) | P-value |
|---|---|---|---|
| Age, years | 76 (52–94) | 73 (31–93) | 0.192 |
| Male/female, n (%) | 98 (68.5)/45 (31.5) | 54 (78.3)/15 (21.7) | 0.148 |
| WHO 2016 classification, n (%) | 0.388 | ||
| MDS-SLD | 2 (1.4) | 1 (1.4) | |
| MDS-MLD | 22 (15.4) | 17 (24.6) | |
| MDS-RS-SLD | 1 (0.7) | 1 (1.4) | |
| MDS-RS-MLD | 6 (4.2) | 2 (2.9) | |
| MDS-EB1 | 54 (37.8) | 17 (24.6) | |
| MDS-EB2 | 55 (38.5) | 28 (40.6) | |
| MDS-U | 3 (2.0) | 3 (4.3) | |
| Hemoglobin level, g/dl | 7.8 (3.5–13.0) | 7.5 (3.2–11.4) | 0.242 |
| Platelet counts, ×109/l | 68.0 (2.0–1139.0) | 50.0 (10.0–685.0) | 0.216 |
| WBC, ×109/l | 2.5 (0.8–24.4) | 2.4 (0.2–42.4) | 0.442 |
| ANC, ×109/l | 1.1 (0.0–19.6) | 1.2 (0.0–23.3) | 0.887 |
| Blast in bone marrow, % | 7.4 (0.0–19.8) | 6.0 (0.0–18.8) | 0.700 |
| Cytogenetic risk defined by IPSS-R, n (%) | 0.515 | ||
| Very good | 2 (1.4) | 0 (0.0) | |
| Good | 34 (23.8) | 16 (23.2) | |
| Intermediate | 33 (23.1) | 16 (23.2) | |
| Poor | 15 (10.5) | 3 (4.3) | |
| Very poor | 59 (41.3) | 34 (49.3) | |
| IPSS-R risk group, n (%) | 0.107 | ||
| Intermediate | 29 (20.3) | 7 (10.1) | |
| High | 39 (27.3) | 26 (37.7) | |
| Very high | 75 (52.4) | 36 (52.2) | |
| RCC transfusion units within 28 days from the start of AZA, days | 4 (0–30) | 4 (0–12) | 0.153 |
| PC transfusion units within 28 days from the start of AZA, days | 0 (0–170) | 0 (0–120) | 0.682 |
| ANC on the 29th day after the start of AZA, ×109/l | 0.4 (0.0–9.3) | 0.5 (0.0–9.8) | 0.793 |
Data presented as median (range) unless otherwise shown. ANC, absolute neutrophil counts; AZA, azacitidine; EB, excess blasts; IPSS-R, Revised International Prognostic Scoring System; MDS, myelodysplastic syndrome; MLD, multilineage dysplasia; PC, platelet concentrate; RCC, red cell concentrates; RS, ring sideroblasts; SLD, single lineage dysplasia; WBC, white blood cells.